{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"400"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"The maximum tolerated dose of oral weekly cyclophosphamide in milligrams (mg), in combination with pomalidomide and dexamethasone. Dose Escalation of Cyclophosphamide, orallly (PO) days 1, 8, 15 as follows: Level 1: 300 mg; Level 2: 400 mg; Level 3: 500 mg. The period for assessment of Dose Limiting Toxicity (DLT) is the first cycle (28 days). The following toxicities will be considered dose limiting if encountered only in the phase I portion of the study: Febrile neutropenia; Grade 3 or 4 non-hematologic toxicity related to treatment with pomalidomide or cyclophosphamide; Participants must have received optimal symptomatic treatment for Grade 3 or 4 nausea, vomiting, or diarrhea to be considered a DLT; Grade 4 transaminitis; Grade 3 transaminitis must be present for ≥ 7 days to be considered a DLT; Grade 4 thrombocytopenia for 7 or more days; Grade 4 neutropenia for 7 or more days.","groups":[{"description":"Phase I: Pomalidomide, high dose dexamethasone and oral cyclophosphamide.","id":"OG000","title":"A: Dose Escalation of Cyclophosphamide"}],"paramType":"NUMBER","populationDescription":"All Phase I Participants.","reportingStatus":"POSTED","timeFrame":"28 Days","title":"Phase I - Maximum Tolerated Dose (MTD)","type":"PRIMARY","unitOfMeasure":"mg"}